Intas Pharma’s Global Leap: UDENYCA® Acquisition Bolsters Biosimilar Dominance
Intas Pharmaceuticals, in a significant move, has acquired UDENYCA® (pegfilgrastim-cbqv) from Coherus BioSciences. This acquisition, completed on August 6, 2025, further cements Intas and its Accord subsidiaries’ position as a global leader in the biosimilar market.
UDENYCA®, a biosimilar to Neulasta® (pegfilgrastim), is a crucial addition to Intas’ expanding portfolio. The deal significantly enhances their reach in the global oncology market, providing wider access to affordable cancer treatments.
This strategic acquisition underscores Intas’ commitment to innovation and affordable healthcare. The company’s global presence and manufacturing capabilities will ensure wider distribution of UDENYCA®, benefiting patients worldwide.
The successful acquisition positions Intas as a key player in the burgeoning biosimilar sector. This development has significant implications for India’s growing pharmaceutical industry and its role in providing affordable medicines globally, especially in the fight against cancer.
